Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
55.96 USD | -0.60% |
|
+0.82% | -32.97% |
Jun. 24 | JPMorgan Cuts Price Target on Cytokinetics to $65 From $77, Maintains Overweight Rating | MT |
Jun. 17 | Cytokinetics Insider Sold Shares Worth $262,750, According to a Recent SEC Filing | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.97% | 6.54B | |
+20.12% | 127B | |
+25.25% | 117B | |
+25.56% | 27.77B | |
-19.51% | 20.44B | |
-14.36% | 16.62B | |
-15.63% | 15.92B | |
-46.67% | 14.94B | |
+11.89% | 14.74B | |
+57.74% | 14.38B |
- Stock Market
- Equities
- CYTK Stock
- News Cytokinetics, Incorporated
- Transcript : Cytokinetics, Incorporated, Q3 2023 Earnings Call, Nov 02, 2023